This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Pooler DB , Ness DB , Sarantopoulos J , Squittieri N , Ravichandran S , Britten CD , Amaravadi RK , Vaishampayan U , LoRusso P , Shapiro GI , Olszanski AJ , Perez R , Gutierrez M , O'Rourke MA , Chung V , Lee JJ , Lewis LD
The effect of sonidegib (LDE225) on the pharmacokinetics of bupropion and warfarin in patients with advanced solid tumours
Br J Clin Pharmacol. 2021 Mar;87(3) :1291-1302
PMID: 32736411 URL: https://www.ncbi.nlm.nih.gov/pubmed/32736411
AbstractAIMS: We evaluated the potential effect of sonidegib at an oral dose of 800 mg once daily (QD) on the pharmacokinetics (PK) of the probe drugs warfarin (CYP2C9) and bupropion (CYP2B6). METHODS: This was a multicentre, open-label study to evaluate the effect of sonidegib on the PK of the probe drugs warfarin and bupropion in patients with advanced solid tumours. Cohort 1 patients received a single warfarin 15-mg dose on Day 1 of the run-in period and on Cycle 2 Day 22 (C2D22) of sonidegib administration. Cohort 2 patients received a single bupropion 75-mg dose on Day 1 of run-in period and on C2D22 of sonidegib administration. Sonidegib 800 mg QD oral dosing began on Cycle 1 Day 1 of a 28-day cycle after the run-in period in both cohorts. RESULTS: The geometric means ratios [90% confidence interval] for (S)-warfarin with and without sonidegib were: area under the concentration-time curve from time 0 to infinity (AUC(inf) ) 1.15 [1.07, 1.24] and maximum plasma concentration (C(max) ) 0.88 [0.81, 0.97]; and for (R)-warfarin were: AUC(inf) 1.10 [0.98, 1.24] and C(max) 0.93 [0.87, 1.0]. The geometric means ratios [90% confidence interval] of bupropion with and without sonidegib were: AUC(inf) 1.10 [0.99, 1.23] and C(max) 1.16 [0.95, 1.42]. Sonidegib 800 mg had a safety profile that was similar to that of lower dose sonidegib 200 mg and was unaffected by single doses of the probe drugs. CONCLUSIONS: Sonidegib dosed orally at 800 mg QD (higher than the Food and Drug Administration-approved dose) did not impact the PK or pharmacodynamics of warfarin (CYP2C9 probe substrate) or the PK of bupropion (CYP2B6 probe substrate).
Notes1365-2125 Pooler, Darcy B Orcid: 0000-0001-9762-9013 Ness, Dylan B Sarantopoulos, John Squittieri, Nicholas Ravichandran, Shoba Britten, Carolyn D Amaravadi, Ravi K Vaishampayan, Ulka LoRusso, Patricia Shapiro, Geoffrey I Olszanski, Anthony J Perez, Raymond Orcid: 0000-0002-7432-2411 Gutierrez, Martin O'Rourke, Mark Allen Chung, Vincent Lee, James J Lewis, Lionel D Orcid: 0000-0003-1164-5157 5P30CA023108/NCI Cancer Center Support Grant/ Novartis Pharma/ Journal Article England Br J Clin Pharmacol. 2020 Jul 31. doi: 10.1111/bcp.14508.